Researchers in Syndey, Australia are taking a different approach to develop a potential coronavirus vaccine. They are testing if a vaccine for tuberculosis can deliver components of the novel coronavirus, repurposing it to develop a COVID-19 vaccine.
The TB vaccine candidate, called BCG:CoVac, is a combination of the TB vaccine, Bacille-Calmette-Guerin (BCG) and major components of the novel coronavirus, the virus that causes COVID-19. After pre-clinical testing of the combination in mice, results revealed that the BCG:CoVac triggered an immune response against coronavirus.
These initial results are promising and could open up an exciting new way of curbing the spread of the coronavirus pandemic if it passes subsequent stages of the vaccine trials.